📊 USNA Key Takeaways
Is Usana Health Sciences Inc. (USNA) a Good Investment?
USANA demonstrates a severe operational deterioration with net income collapsing 72.7% YoY despite 8.3% revenue growth, indicating margin compression and cost control failures. While the company maintains a fortress balance sheet with no debt and $162.8M cash, weak operating cash flow of $9.8M and minimal 3.0% net margins signal fundamental business challenges that outweigh financial stability.
Usana Health Sciences Inc. Key Strengths (USNA)
- Exceptional gross margin of 76.2% demonstrates strong product pricing power and cost control at production level
- Fortress balance sheet with zero long-term debt and $162.8M cash provides strategic flexibility and downside protection
- Strong liquidity metrics (2.51x current ratio, 1.69x quick ratio) ensure short-term financial stability and operational continuity
USNA Stock Risks: Usana Health Sciences Inc. Investment Risks
- Net income and EPS collapsed 72-73% YoY despite revenue growth, indicating severe operational dysfunction or one-time charges
- Anemic profitability with 3.0% net margin and 5.5% operating margin leaves minimal cushion for market volatility
- Weak cash generation with $9.8M operating cash flow and $7.1M free cash flow is insufficient for sustainable business operations
- Dramatically poor returns on equity (1.4%) and assets (1.0%) suggest capital is being deployed inefficiently
Key Metrics to Watch
- Operating cash flow trend and path to $15M+ annual OCF sustainability
- Net margin recovery trajectory and operating expense rationalization
- Insider Form 4 filing volume and directionality (sells vs. buys) as signal of management confidence
Usana Health Sciences Inc. (USNA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.8% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.51x current ratio provides a solid financial cushion.
USNA Profit Margin, ROE & Profitability Analysis
USNA vs Materials Sector: How Usana Health Sciences Inc. Compares
How Usana Health Sciences Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Usana Health Sciences Inc. Stock Overvalued? USNA Valuation Analysis 2026
Based on fundamental analysis, Usana Health Sciences Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Usana Health Sciences Inc. Balance Sheet: USNA Debt, Cash & Liquidity
USNA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Usana Health Sciences Inc.'s revenue has declined by 22% over the 5-year period, indicating business contraction. The most recent EPS of $3.30 reflects profitable operations.
USNA Revenue Growth, EPS Growth & YoY Performance
USNA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $249.5M | $7.5M | $0.41 |
| Q3 2025 | $200.2M | -$6.5M | $-0.36 |
| Q2 2025 | $212.9M | $9.7M | $0.52 |
| Q1 2025 | $227.8M | $9.4M | $0.49 |
| Q3 2024 | $200.2M | $10.6M | $0.56 |
| Q2 2024 | $212.9M | $10.4M | $0.54 |
| Q1 2024 | $227.8M | $16.5M | $0.86 |
| Q3 2023 | $213.4M | $11.3M | $0.59 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Usana Health Sciences Inc. Dividends, Buybacks & Capital Allocation
USNA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Usana Health Sciences Inc. (CIK: 0000896264)
📋 Recent SEC Filings
❓ Frequently Asked Questions about USNA
What is the AI rating for USNA?
Usana Health Sciences Inc. (USNA) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are USNA's key strengths?
Claude: Exceptional gross margin of 76.2% demonstrates strong product pricing power and cost control at production level. Fortress balance sheet with zero long-term debt and $162.8M cash provides strategic flexibility and downside protection.
What are the risks of investing in USNA?
Claude: Net income and EPS collapsed 72-73% YoY despite revenue growth, indicating severe operational dysfunction or one-time charges. Anemic profitability with 3.0% net margin and 5.5% operating margin leaves minimal cushion for market volatility.
What is USNA's revenue and growth?
Usana Health Sciences Inc. reported revenue of $250.2M.
Does USNA pay dividends?
Usana Health Sciences Inc. does not currently pay dividends.
Where can I find USNA SEC filings?
Official SEC filings for Usana Health Sciences Inc. (CIK: 0000896264) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is USNA's EPS?
Usana Health Sciences Inc. has a diluted EPS of $0.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is USNA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Usana Health Sciences Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is USNA stock overvalued or undervalued?
Valuation metrics for USNA: ROE of 1.4% (sector avg: 14%), net margin of 3.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is USNA's AI grade for 2026?
Our dual AI analysis gives Usana Health Sciences Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is USNA's free cash flow?
Usana Health Sciences Inc.'s operating cash flow is $9.8M, with capital expenditures of $2.6M. FCF margin is 2.8%.
How does USNA compare to other Materials stocks?
Vs Materials sector averages: Net margin 3.0% (avg: 10%), ROE 1.4% (avg: 14%), current ratio 2.51 (avg: 1.6).